Bellerophon therapeutics, inc. (BLPH)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

8,595

9,874

12,838

16,798

20,679

16,645

19,552

23,403

28,350

28,823

32,283

10,968

13,539

14,202

3,930

1,304

1,270

6,260

23,908

48,509

62,935

16,815

Restricted cash

103

103

102

102

101

101

255

404

403

402

0

150

150

401

-

-

-

0

3,863

6,179

8,497

9,264

Marketable securities

-

-

-

-

-

-

998

2,496

2,994

2,996

3,178

3,901

3,113

5,571

7,230

11,920

16,088

17,807

17,391

-

-

0

Short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,165

-

-

Receivables - Due from Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

250

167

-

-

Receivables - Due from Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

167

-

Prepaid expenses and other current assets

349

405

712

825

948

650

1,738

2,491

3,016

3,359

3,934

5,362

6,442

6,331

6,365

5,405

5,727

5,385

1,444

1,839

1,974

1,602

Total current assets

9,047

10,382

13,652

17,725

21,728

17,396

22,543

28,794

34,763

35,580

39,395

20,381

23,244

26,505

17,525

18,629

23,085

29,452

46,856

60,859

73,573

27,681

Restricted cash, non-current

300

300

300

300

300

300

300

150

150

150

300

307

307

307

457

457

457

457

457

-

-

1,548

Right of use assets, net

1,961

2,110

2,256

2,065

2,189

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,466

Other non-current assets

-

-

-

-

-

-

44

26

40

54

59

462

909

1,491

3,304

5,595

5,985

6,701

-

-

-

0

Property and equipment, net

270

316

401

488

576

664

755

845

935

1,026

1,116

1,207

1,300

1,399

1,498

1,597

1,695

1,799

1,847

1,513

1,604

1,696

Total assets

11,578

13,108

16,609

20,578

24,793

18,360

23,642

29,815

35,888

36,810

40,870

22,357

25,760

29,702

22,784

26,278

31,222

38,409

49,160

62,372

75,177

33,391

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

2,220

3,106

2,264

2,822

2,638

2,755

4,371

4,056

4,593

3,853

2,755

2,834

3,944

2,807

2,235

2,020

641

1,613

934

966

659

376

Accrued research and development

1,785

2,117

2,581

2,580

3,187

3,771

3,823

4,078

2,987

1,785

1,873

1,821

1,183

2,573

1,085

2,394

3,487

4,078

3,041

6,103

7,235

6,666

Accrued expenses

2,101

1,703

1,488

752

885

1,013

880

905

816

1,441

1,784

838

717

1,115

1,302

1,673

3,036

2,234

3,438

2,832

3,825

2,751

Current portion of operating lease liabilities

669

658

647

556

547

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due to Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

216

-

166

126

159

148

1,231

1,251

-

661

Due to Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,069

-

Total current liabilities

6,775

7,584

6,980

6,710

7,257

7,539

9,074

9,039

8,396

7,079

6,412

5,493

6,060

6,495

4,788

6,213

7,323

8,073

8,644

11,152

12,788

10,454

Long term operating lease liabilities

1,489

1,659

1,828

1,739

1,882

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock warrant liabilities

1,168

274

452

667

5,349

-

10,641

28,551

25,275

-

18,784

17,651

18,900

-

-

-

-

-

-

-

-

-

Warrants and Rights Outstanding

-

-

-

-

-

6,965

-

-

-

32,325

-

-

-

5,215

-

-

-

0

-

-

-

-

Total liabilities

9,432

9,517

9,260

9,116

14,488

14,504

19,715

37,590

33,671

39,404

25,196

23,144

24,960

11,710

4,788

6,213

7,323

8,073

8,644

11,152

12,788

10,454

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders’ equity:
Common stock, $0.01 par value per share; 200,000,000 shares authorized and 4,857,393 and 4,580,127 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

49

46

689

689

689

39

587

578

574

569

550

352

330

317

145

139

135

131

130

129

129

-

Preferred stock, $0.01 par value per share; 5,000,000 shares authorized, zero shares issued and outstanding at March 31, 2020 and December 31, 2019

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

Additional paid-in capital

196,830

193,308

192,343

192,169

186,907

180,313

178,925

178,335

176,862

176,151

170,275

146,426

144,105

142,167

134,921

132,798

131,499

130,902

130,237

129,801

129,387

-

Accumulated other comprehensive loss

-

-

-

-

-

-

-1

-3

-5

-4

0

0

0

0

-1

2

2

-19

1

-

-

-

Membership units, no par value per unit; 94,273,819 voting units authorized, 7,524,196 voting units issued and outstanding at December 31, 2014; 19,416,481 non-voting units authorized, 381,129 non-voting units issued and outstanding at December 31, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

77,156

Accumulated deficit

-194,733

-189,763

-185,683

-181,396

-177,291

-176,496

-175,584

-186,685

-175,214

-179,310

-155,151

-147,565

-143,635

-124,492

-117,069

-112,874

-107,737

-100,678

-89,852

-78,710

-67,127

-54,219

Stockholders' Equity Attributable to Parent

2,146

3,591

7,349

11,462

10,305

3,856

3,927

-7,775

2,217

-2,594

15,674

-787

800

17,992

17,996

20,065

23,899

30,336

40,516

51,220

62,389

22,937

Total liabilities and stockholders’ equity

11,578

13,108

16,609

20,578

24,793

18,360

23,642

29,815

35,888

36,810

40,870

22,357

25,760

29,702

22,784

26,278

31,222

38,409

49,160

62,372

75,177

33,391